See more : The Necessity Retail REIT, Inc. (RTLPO) Income Statement Analysis – Financial Results
Complete financial analysis of Zynerba Pharmaceuticals, Inc. (ZYNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zynerba Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Steel Strips Wheels Limited (SSWL.BO) Income Statement Analysis – Financial Results
- PayGroup Limited (PYG.AX) Income Statement Analysis – Financial Results
- WesCan Energy Corp. (GPIPF) Income Statement Analysis – Financial Results
- Sanbase Corporation Limited (8501.HK) Income Statement Analysis – Financial Results
- Rapid Nutrition PLC (ALRPD.PA) Income Statement Analysis – Financial Results
Zynerba Pharmaceuticals, Inc. (ZYNE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zynerba.com
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.10M | 21.42M | 35.65M | 20.38M | 27.25M | 22.81M | 16.78M | 7.45M | 2.40M | 1.13M |
| General & Administrative | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Cost & Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Interest Income | 846.86K | 21.05K | 243.99K | 1.52M | 961.32K | 519.55K | 80.22K | 0.00 | 0.00 | 0.00 |
| Interest Expense | -215.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 631.13K | 559.68K | -481.72K | 145.91K | 99.57K | 94.21K | 75.30K | 26.03K | 27.06K | 49.39K |
| EBITDA | -34.62M | -36.21M | -52.06M | -34.17M | -40.40M | -32.82M | -23.21M | -12.51M | -5.64M | -585.05K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,422.28% | -456,747.03% | -316,123.92% | -4,483.73% | -696.37% | -61.98% |
| Operating Income | -35.25M | -36.77M | -52.06M | -34.32M | -40.40M | -32.82M | -23.21M | -12.53M | -5.67M | -634.44K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,974.22% | -452,731.16% | -320,105.21% | -4,493.07% | -699.71% | -67.21% |
| Total Other Income/Expenses | 215.73K | -538.63K | 725.71K | 1.38M | 486.66K | 810.71K | -208.42K | 7.35K | -1.84K | -2.35K |
| Income Before Tax | -35.04M | -37.31M | -51.34M | -32.94M | -39.91M | -32.01M | -23.42M | -12.52M | -5.67M | -636.79K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,980.00% | -4,490.43% | -699.94% | -67.46% |
| Income Tax Expense | -215.73K | 291.49K | -932.75K | -1.51M | 486.66K | -27.54K | -27.54K | 27.54K | 0.00 | 0.00 |
| Net Income | -34.82M | -37.60M | -50.40M | -31.43M | -39.91M | -32.01M | -23.39M | -12.55M | -5.67M | -636.79K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,600.10% | -4,500.30% | -699.94% | -67.46% |
| EPS | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| EPS Diluted | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| Weighted Avg Shares Out | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
| Weighted Avg Shares Out (Dil) | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Fragile X Syndrome - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Fragile X Syndrome pipeline...
Why Shares of Harmony Bioscience Are Falling on Friday
Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter revenue was up 25%, year over year.
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept...
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender...
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences...
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its...
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome...
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zynerba Pharmaceuticals, Inc. (NasdaqCM: ZYNE) to Harmony Biosciences Holdings, Inc. (NasdaqGM:...
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zynerba Pharmaceuticals, Inc. (NasdaqCM: ZYNE) to Harmony Biosciences Holdings, Inc. (NasdaqGM:...
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ: ZYNE ) skyrocketed on Monday following an announcement early this morning of a buyout. Specifically, Harmony Biosciences (NASDAQ: HRMY ) — which focuses on innovative therapies...
Source: https://incomestatements.info
Category: Stock Reports